Clinical Innovations Inc is categorized under Medical Labs in Santa Ana, CA and active since 2002.
Clinical Innovations Inc was established in 2002, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Medical Labs business, which does work in the B2C market, and is classified as a Medical Labs, under code number 6211110 by the NAICS.
If you are seeking more information, feel free to contact Pauline Bucci, Director at the company’s single location by writing to 801 North Tustin Avenue # 600, Santa Ana, California CA 92705 or by phoning (714) 547-4100. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Clinical Innovations Inc |
Contact Person: | Pauline Bucci, Director |
Address: | 801 North Tustin Avenue # 600, Santa Ana, California 92705 |
Phone Number: | (714) 547-4100 |
Website Address: | citrials.com |
Annual Revenue (USD): | $1.000.000 to $2.499.999 |
Founded: | 2002 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2C (Business to Consumer) |
Business Category: | Medical Labs |
SIC Code: | 8071 |
NAICS Code: | 6211110 |
Share This Business: |
Clinical Innovations Inc was started in 2002 to provide professional Medical Labs under the SIC code 8071 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact Pauline Bucci, Director for inquiries that concern Clinical Innovations Inc by calling the company number (714) 547-4100, as your correspondence is most welcome. Additionally, the physical location of the single location of Clinical Innovations Inc can be found at the coordinates 33.751866,-117.834122 as well as the street address 801 North Tustin Avenue # 600 in Santa Ana, California 92705.
For its online presence, you may visit Clinical Innovations Inc’s website at citrials.com and engage with its social media outlets through on Twitter and on Facebook.